EGFR and lung cancer: EGFR targeted therapies have been approved as monotherapies and combination therapies in diverse cancers such as non–small-cell lung cancer (Shepherd et al., 2005), pancreatic cancer (Moore et al., 2007), colorectal cancer (Kennecke et al., 2013), breast cancer (Nelson and Dolder, 2006) and head and neck cancer (Baba et al., 2012).